Search clinical trials for: Multiple Sclerosis, MS, CNS, Daclizumab

Total 12781 results

Novartis Pharmaceuticals

Completed

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis (OCTIMS)

Multiple Sclerosis | RRMS

Spain, Czechia, Germany, Australia, Italy, Switzerland, Denmark, United States, United Kingdom, Canada, Netherlands, Poland
Synthon BV

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
Novartis Pharmaceuticals

Not yet recruiting

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Multiple Sclerosis, Relapsing-Remitting
Ain Shams University

Recruiting

Dalfampridine in Egyptian Patients With Multiple Sclerosis

Multiple Sclerosis

Egypt
Novartis Pharmaceuticals

Completed

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

Multiple Sclerosis

United States
Novartis Pharmaceuticals

Completed

Risk Perception in Multiple Sclerosis

Multiple Sclerosis

United States
Enzyvant Therapeutics GmBH
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaborators

Completed

Phase I/II Thymus Transplantation With Immunosuppression #950 (#950)

DiGeorge Anomaly | Complete DiGeorge Anomaly | Complete DiGeorge Syndrome | Complete Atypical DiGeorge Anomaly | Complete Atypical DiGeorge Syndrome

United States
Biogen
AbbVie

Terminated

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (EXTEND)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
University of Maryland, Baltimore

Completed

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Institute of Neurological Disorders and...

Completed

Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Biogen
AbbVie

Terminated

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab (SUSTAIN)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy, United States, Canada, Germany, Puerto Rico
Novartis Pharmaceuticals

Terminated

Effect of Fingolimod on Neurodegeneration

Cognition | Brain Volume Loss

Turkey
Institut National de la Santé Et de la Recherche...

Unknown

PET With [18F]Flumazenil as an Index of Neurodegeneration in MS (FLUMA-SEP-T)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

Relapsing-Remitting Multiple Sclerosis

Germany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
National Institute of Neurological Disorders and...

Completed

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Completed

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (OBSERVE)

Relapsing-Remitting Multiple Sclerosis

Poland, Hungary, United States, Czech Republic
Novartis Pharmaceuticals

Completed

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Von Hippel-Lindau Disease | Retinal Hemangioblastoma | CNS Hemangioblastoma

United States
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (SELECTION)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Biogen
AbbVie

Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))

Relapsing-Remitting Multiple Sclerosis

Sweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation, Ukraine, Czech Republic
Fondazione Don Carlo Gnocchi Onlus

Completed

Stabilometric Assessment of Balance Recovery in Persons With Multiple Sclerosis

Multiple Sclerosis

Italy
Bayer

Withdrawn

QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Multiple Sclerosis, Relapsing-Remitting

Korea, Republic of
National Institute of Neurological Disorders and...

Completed

Zenapax to Treat Multiple Sclerosis

Multiple Sclerosis

United States
PDL BioPharma, Inc.

Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
NeuFit - Neurological Fitness and Education

Recruiting

Impact of Direct Current Electrical Stimulation on Treatment of Lumbosacral Radiculopathy

Radiculopathy Lumbar | Radiculopathy Sacral | Radiculopathy Multiple Sites

United States
Ontario Clinical Oncology Group (OCOG)
Pfizer

Not yet recruiting

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE)

Refractory Multiple Myeloma

Canada
UGECAM Rhône-Alpes

Recruiting

Efficiency of Spatially Distributed Sequential Stimulation (Sdss) for Functional Electrical Stimulation (FES) of Upper Motor Neuron Syndrome (UMR) Patients (SDSS_UMS)

Upper Motor Neuron Disease

France
Peking University People's Hospital
Xingtai People's Hospital; Hebei Provincial People's Hospital

Not yet recruiting

Efficacy and Safety of an Artificial-pancreas-like Learning-based Control in Type 1 Diabetes on Multiple Daily Injection Therapy (ELITE)

Diabetes Mellitus, Type 1
Emory University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Automated Insulin Delivery for Inpatients With Dysglycemia (AIDING)

Type 1 Diabetes | Type 2 Diabetes

United States
Nantes University Hospital

Not yet recruiting

Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study (DELICATESSE)

Myeloma Multiple
University Hospital, Brest

Not yet recruiting

Evolution of the Lymphocyte Phenotype in Patients With Infection in Intensive Care Unit (REAPHEN)

Patients Undergoing Esophagectomy | Patients With Severe Polytrauma | Patients With Severe Neurological Lesion | Patients With Abdominal Infection
Robert Simpson

Not yet recruiting

Implementation of Online Mindfulness-Based Stress Reduction Tailored for People With Multiple Sclerosis

Multiple Sclerosis
Ultragenyx Pharmaceutical Inc

Not yet recruiting

Long-term Extension of GTX-102 in Angelman Syndrome

Angelman Syndrome

United States, Australia, Canada, Germany, United Kingdom, Israel, France, Spain
Shirley Ryan AbilityLab
Northwestern University

Not yet recruiting

The Synergistic Effects of AIH and FES in Persons With MS

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive

United States
Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
Eli Lilly and Company

Not yet recruiting

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Glioma

United States
University of Vermont

Not yet recruiting

Home-based Balance Training in Adults With Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, MS
University of Illinois at Chicago

Not yet recruiting

Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device (MSGH)

Multiple Sclerosis
Jules Bordet Institute
RayzeBio, Inc.

Not yet recruiting

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression

Belgium
Celgene

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Celgene

Not yet recruiting

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
University Hospital, Angers

Not yet recruiting

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. (ALHERT)

Lymphoma | Leukemia | Multiple Myeloma

France
Riphah International University

Not yet recruiting

Effects of Lower Limb Fitness Program in Children With DS

Down Syndrome

Pakistan
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Study of CT071 Injection in HRNDMM

High-risk Newly Diagnosed Multiple Myeloma (HRNDMM)
Wave Life Sciences Ltd.

Not yet recruiting

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD (RestorAATion-2)

Alpha-1 Antitrypsin Deficiency
Marta Bassi
University of Catania; San Luigi Gonzaga Hospital; University of Florence; University... and other collaborators

Recruiting

Supporting Mental Health in Daily Life After the Diagnosis of Multiple Sclerosis (MindFlowMS)

Multiple Sclerosis

Italy
Traws Pharma, Inc.

Recruiting

Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers

Healthy Volunteers Only

Australia
Eilean Therapeutics

Recruiting

Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers

AML

Australia

Search clinical trials for: Multiple Sclerosis, MS, CNS, Daclizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations